Kalaris Therapeutics, Inc. balance sheet KLRS

Annual Quarterly

As of Jun 30, 2026, Kalaris Therapeutics, Inc. had total assets of $99.5 million and total liabilities of $41.9 million. Total assets were up 7.2% from a year earlier. Stockholders' equity was $57.7 million. It held $93.5 million in cash and investments against $1.4 million of total debt, net cash of $92.1 million. The current ratio, current assets divided by current liabilities, was 10.98.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Q3 FY2024
Sep 30, 2024
Assets
Cash
43
-51.2%
34
-65.9%
98
+5882.6%
42
+2115.7%
88
+1317.3%
101
+1831.6%
2
-98.2%
2
-98.0%
Short-term investments
50
63
20
35
+592.9%
—
—
0
-100.0%
5
-95.8%
Long-term investments
—
8
0
—
—
—
—
—
Cash and investments
94
+5.8%
105
+3.9%
118
+7098.4%
77
+1014.6%
88
+184.2%
101
+69.1%
2
-99.1%
7
-96.8%
Total current assets
96
+4.7%
98
-3.6%
119
+4459.1%
78
-36.2%
92
-29.5%
102
-27.8%
3
-98.6%
123
-44.3%
Total assets
100
+7.2%
110
+6.5%
122
+1875.6%
81
-33.8%
93
-29.1%
103
-28.5%
6
-96.8%
123
-50.7%
Liabilities and equity
Accounts payable
1
-69.5%
1
-61.9%
1
-17.9%
0
+868.6%
4
+3245.5%
2
+210.3%
2
-76.9%
0
-98.7%
Total current liabilities
9
+14.2%
8
+13.1%
10
-60.7%
6
+329.5%
8
+224.3%
7
-6.7%
25
-12.9%
1
-95.7%
Total liabilities
42
+5.4%
41
+5.2%
43
-24.4%
39
+2684.0%
40
+271.5%
39
+65.5%
57
+26.1%
1
-97.3%
Stockholders' equity
58
+8.6%
69
+7.3%
79
+181.6%
42
+146.8%
53
+203.1%
64
+234.4%
-97
-114.6%
-89
-145.8%
Debt
Lease liabilities
1
1
1
-94.7%
2
—
0
-100.0%
—
—
Total debt
1
1
1
-94.7%
2
—
0
-100.0%
—
—
Net cash
92
103
+2.5%
117
+551.9%
75
—
101
+144.0%
—
—
Ratios
Current ratio
10.98x
12.19x
12.23x
12.89x
11.98x
14.31x
0.11x
86.78x
Debt to equity
0.02x
0.02x
0.02x
0.04x
—
0.00x
—
—
Return on equity
-76.75%
-64.32%
-55.11%
-132.49%
-153.73%
-118.92%
—
—
Return on assets
-44.47%
-40.16%
-35.68%
-68.33%
-87.95%
-73.68%
-1,122.48%
-87.19%
Book value per share
2.42
2.98
3.44
2.24
2.84
3.42
-71.23
-0.77
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
KLRS (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Berkeley Heights, NJ
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1754068
Former names
Allovir, Inc. (until Mar 12, 2025); ViraCyte, Inc. (until Oct 2, 2018)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.